Skip to main content
Premium Trial:

Request an Annual Quote

RXi Posts Higher Q1 Losses on Increased Spending


RXi Pharmaceuticals last week reported that its first-quarter net loss swelled 38 percent on rising research and development and general and administrative costs.

For the three-month period ended March 31, RXi's net loss climbed to $4.2 million, or $0.30 per share, from a year-ago loss of $2.6 million, or $0.21 per share.

R&D expenses in the quarter jumped roughly 27 percent, to $1.4 million from $1.1 million, primarily due to higher employee compensation costs and legal expenses related to patent applications filed on internal inventions, RXi said.

General and administrative costs in the quarter rose to $2.8 million from $1.6 million in the same period a year ago, which the firm attributed to higher non-cash costs associated with warrants issued for business advisory services.

At the end of the quarter, RXi had $7.2 million in cash and cash equivalents.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.